// App-Quantinova.ai

: Combined Inhibition of MCL1 By AZD5991 and BCL2/Bclxl By AZD4320 As Promising Strategies to Overcome Acute Leukemia Tumor Burden and Niche Chemoresistance

Researchers

Presenter

  • Maura Lima Pereira Bueno

Principal Investigators

  • Leonardo Artico

  • Adriana Silva Santos Duarte

  • Audrey Basso

  • Jose Andres Yunes

  • Sara T. Olalla Saad

  • Fernanda Marconi Roversi

Medical Centers

  • Boldrini Children's Center, Campinas, SP, Brasil, Campinas, Brazil

  • Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil

  • Hematology and Transfusion Medicine Center-University of Campinas/Hemocentro-UNICAMP, UNICAMP, Campinas, Brazil

Locations

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute Leukemia

Biomarkers

  • B-cell lymphoma 2

  • Myeloid Cell Leukemia 1

  • Breakpoint Cluster Region

  • Cluster of Differentiation 34

  • Cluster of Differentiation 55

  • Proto-oncogene tyrosine-protein kinase ROS

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Nitric oxide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved